Filippa Stenberg
Directeur/Membre du Conseil chez SWEDISH ORPHAN BIOVITRUM AB
Fortune : 13 599 $ au 30/04/2024
Postes actifs de Filippa Stenberg
Sociétés | Poste | Début | Fin |
---|---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Directeur/Membre du Conseil | - | - |
Independent Dir/Board Member | - | - | |
INVESTOR AB | Corporate Officer/Principal | - | - |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Gestionnaire de Portefeuille-Actions | 01/01/2017 | - |
Analyst-Equity | 01/01/2012 | 01/12/2013 |
Historique de carrière de Filippa Stenberg
Anciens postes connus de Filippa Stenberg
Sociétés | Poste | Début | Fin |
---|---|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - | - |
Swedbank AB (Broker) | Sales & Marketing | 22/08/2011 | - |
Formation de Filippa Stenberg
Stockholm School of Economics | Graduate Degree |
Statistiques
Internationale
Suède | 7 |
Opérationnelle
Corporate Officer/Principal | 2 |
Sales & Marketing | 1 |
Analyst-Equity | 1 |
Sectorielle
Finance | 4 |
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
INVESTOR AB | Finance |
Entreprise privées | 3 |
---|---|
Swedbank AB (Broker) | Finance |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Finance |
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
- Bourse
- Insiders
- Filippa Stenberg
- Expérience